IRIS
NATOLI, Clara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.187
EU - Europa 5.347
AS - Asia 2.095
Continente sconosciuto - Info sul continente non disponibili 17
SA - Sud America 11
AF - Africa 9
OC - Oceania 4
Totale 13.670
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.175
CN - Cina 1.098
IE - Irlanda 1.030
UA - Ucraina 905
SE - Svezia 768
IT - Italia 685
FR - Francia 676
TR - Turchia 613
GB - Regno Unito 554
DE - Germania 307
IN - India 169
RU - Federazione Russa 139
FI - Finlandia 132
SG - Singapore 124
VN - Vietnam 69
BE - Belgio 46
AT - Austria 29
CZ - Repubblica Ceca 29
EU - Europa 17
PL - Polonia 10
CA - Canada 9
IL - Israele 6
BR - Brasile 5
EG - Egitto 5
NL - Olanda 5
AU - Australia 4
CH - Svizzera 4
DK - Danimarca 4
GR - Grecia 4
ID - Indonesia 4
RO - Romania 4
CL - Cile 3
ES - Italia 3
HR - Croazia 3
JP - Giappone 3
HK - Hong Kong 2
IR - Iran 2
MX - Messico 2
PY - Paraguay 2
AM - Armenia 1
BG - Bulgaria 1
BS - Bahamas 1
DZ - Algeria 1
EE - Estonia 1
HU - Ungheria 1
LT - Lituania 1
LU - Lussemburgo 1
MA - Marocco 1
MK - Macedonia 1
MT - Malta 1
NG - Nigeria 1
PK - Pakistan 1
PT - Portogallo 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TW - Taiwan 1
UZ - Uzbekistan 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 13.670
Salva come PNG Salva come JPEG
Città #
Chandler 1.490
Jacksonville 1.173
Dublin 1.021
Princeton 468
Southend 418
Izmir 376
Nanjing 343
Ashburn 270
Wilmington 225
Beijing 207
Dearborn 189
Ann Arbor 177
Cambridge 175
Altamura 168
Boardman 150
Chieti 138
Nanchang 126
Woodbridge 93
Houston 80
New York 77
Singapore 70
Dong Ket 68
Shenyang 62
Hebei 60
Kunming 52
Tianjin 49
Brussels 46
Los Angeles 45
Washington 43
Jiaxing 40
Norwalk 37
Vienna 29
Brno 22
Changsha 22
Falls Church 22
Rome 21
Hangzhou 20
Seattle 20
Kocaeli 19
San Mateo 17
Lanzhou 16
Pescara 15
Auburn Hills 14
Tappahannock 14
Changchun 13
Grevenbroich 13
Augusta 11
Chicago 11
Guangzhou 11
Ningbo 11
Düsseldorf 10
Edinburgh 10
Frontone 10
Jinan 9
Leawood 9
London 9
Fairfield 8
Giaveno 8
Helsinki 8
Milan 8
Moscow 8
Aprilia 7
Hefei 7
Shanghai 7
Zhengzhou 7
Collecorvino 6
Giulianova 6
Menlo Park 6
Orange 6
Bristol 5
Cairo 5
Monmouth Junction 5
Mumbai 5
Munich 5
Pune 5
Redwood City 5
Anzio 4
Denver 4
Napoli 4
Olomouc 4
Paris 4
Shaoxing 4
Spoltore 4
Toronto 4
Altino 3
Ameno 3
Amsterdam 3
Avellino 3
Clifton 3
Copenhagen 3
Francavilla al Mare 3
Haikou 3
Hanover 3
Jinhua 3
Keputih 3
Leicester 3
Montreal 3
Penne 3
Phoenix 3
Rossano Veneto 3
Totale 8.521
Salva come PNG Salva come JPEG
Nome #
Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer 111
A multidisciplinary group for prostate cancer management: A single institution experience 106
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 105
Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis 103
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 98
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 95
Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patients survival. 95
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 95
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases 93
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 93
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 93
Glicomimetici quali potenziali nuovi farmaci per la prevenzione delle metastasi. 92
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 91
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 91
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 89
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer 87
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 86
90K (Mac-2 BP) in human milk 85
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 85
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 84
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 83
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 82
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 82
Chemotherapy preoperative for the management of breast cancer locally advanced 82
Unknown primary tumors 82
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 82
Gli analoghi sintetici delle glicoamine come potenziali nuovi farmaci nella prevenzione delle metastasi 81
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction 81
Principali effetti collaterali delle terapie mediche 81
90K protein in HIV infection: evidence of its release from peripheral blood mononuclear cells 80
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 80
A phase II study of cisplatin, epirubicin, vindesine chemotherapy and lonidamine in advanced nonsmall cell lung cancer 79
A novel serum test using interferon for early detection of tumor reccurrence in cancer patients after radical surgery. 79
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 79
null 79
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin 79
Surgical treatment of adrenal metastases from non small cell lung cancer 78
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 78
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer 77
Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey 77
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 76
null 76
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study 76
ABIRATERONE ACETATE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHEMOTHERAPY-NAIVE PATIENTS: AN ITALIAN MULTICENTER 'REAL-LIFE' 1-YEAR STUDY 76
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study 76
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 75
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study 75
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer 75
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study. 74
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 74
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. 74
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 74
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 73
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 73
Prognostic value of a novel circulating serum 90K antigen in breast cancer 73
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 73
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 73
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience 73
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 73
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 73
90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells 72
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 72
Prognostic value of 90K protein in HIV infection 71
Preoperative dose-dense sequential chemotherapy of epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with breast cancer 71
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 71
Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis 71
TGF-β-1 increases 90K tumor associated antigen gene expression by increasing upstream regulatory factor binding to the minimal promoter. 70
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 70
DNA ploidy and S-phase fraction in pulmonary carcinoids. 70
Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: A systematic review 70
Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts 70
BIOLOGICAL INDICATORS OF PROGNOSIS IN HUMAN CANCER: AN EMERGING ROLE FOR LECTIN GALACTOSIDE-BINDING SOLUBLE 3-BINDING PROTEIN (LGALS3BP) 70
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 70
La stimolazione dinamica con IFN-α per la diagnosi precoce di ripresa di malattia in pazienti NED 69
null 69
Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. 68
CYLOOXYGENASE-INDEPENDENT INDUCTION OF THE TUMOR SUPPRESSOR PROTEIN P21WAF-1/CIP1 AND DIFFERENTIATION BY L-745,337, A SELECTIVE COX-2 INHIBITOR, AND SODIUM SALICYLATE, IN HT-29 COLON CANCER CELLS. 68
BIOCHEMICAL AND PHARMACOLOGICAL CHARACTERIZATION OF CYCLOOXYGENASE ACTIVITY OF HUMAN BLOOD PROSTAGLANDIN ENDOPEROXIDE SYNTHASES. 68
Elevated serum levels of a 90,000 daltons tumor-associated antigen in cancer and in infection by human immunodeficiency virus (HIV). 68
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 68
Triple positive early breast cancer in the pre- and post Trastuzumab eras: a subgroup analysis of a multicenter retrospective study. 68
45: L’UTILIZZO DELL’IMMUNOTERAPIA PER IL TRATTAMENTO DELL’ADENOCARCINOMA POLMONARE IN II LINEA: NIVOLUMAB VS PEMBROLIZUMAB 68
Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study. 68
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 68
Expression of tumor associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen 67
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 67
Lipoprotein 90K in human immunodeficiency virus-infected patients: a further serologic marker of progression. 67
Rivaroxaban for cancer-associated cardiac thrombosis 67
Tyrosine kinase inhibitors 67
Combined therapy in pancreatic cancer 66
A Flow cytometric study of early gastric cancer 66
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. 66
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 66
Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study 66
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 66
Circadian timing of chemotherapeutic agents:a phase II study of 5-fluoro-2-deoxyuridine in gastrointestinal cancer and renal cell carcinoma 65
Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer 65
Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies? 65
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study 65
null 65
Totale 7.687
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.323
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.323
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.057 966 170 39 109 248 203 309 224 169 271 324 25
2020/20211.463 229 22 279 12 91 288 34 43 98 152 85 130
2021/20221.095 23 33 8 193 115 26 23 70 78 28 131 367
2022/20233.890 311 475 271 472 394 727 203 329 450 38 135 85
2023/20241.604 131 56 119 48 126 558 289 49 25 50 16 137
2024/2025186 186 0 0 0 0 0 0 0 0 0 0 0
Totale 14.507